Mitobridge company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mitobridge.com

Total Raised

$45M

Investors Count

3

Deal Terms

2

Mitobridge Funding, Mitobridge Valuation & Mitobridge Revenue

2 Fundings

Mitobridge's latest funding round was a Acquired for on December 1, 2017.

Mitobridge's valuation in October 2013 was $16.32M.

Mitobridge's latest post-money valuation is from December 2017.

Sign up for a free trial to see Mitobridge's valuations in December 2017 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/1/2017

Acquired

$99M

0

FY undefined

1

10/7/2013

Series A

$99M

$16.32M

0

FY undefined

10

Date

12/1/2017

10/7/2013

Round

Acquired

Series A

Amount

$99M

Investors

Valuation

$99M

$16.32M

Revenue

0

FY undefined

0

FY undefined

Sources

1

10

Mitobridge Deal Terms

2 Deal Terms

Mitobridge's deal structure is available for 2 funding rounds, including their Acquired from December 01, 2017.

Round

Acquired

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

$99M

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Mitobridge Investors

3 Investors

Mitobridge has 3 investors. Astellas Venture Management invested in Mitobridge's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/7/2013

12/1/2017

2
Series A, Acquired (2017)

Corporate Venture

California

00/00/0000

00/00/0000

MPM Capital

Subscribe to see more

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Longwood Fund

Subscribe to see more

Venture Capital

Massachusetts

First funding

10/7/2013

00/00/0000

00/00/0000

Last Funding

12/1/2017

00/00/0000

00/00/0000

Investor

MPM Capital

Longwood Fund

Rounds

2
Series A, Acquired (2017)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporate Venture

Venture Capital

Venture Capital

Location

California

Massachusetts

Massachusetts

You May Also Like

MISSION Therapeutics Logo
MISSION Therapeutics

MISSION Therapeutics is a private drug discovery company focused on elucidating and targeting the ubiquitin pathway to treat cancers and other diseases. The company develops small molecule drugs that target deubiquitylating enzymes (DUBs) involved in the DNA damage response, with the aim of inducing synthetic lethality, a powerful mechanism to selectively kill specific tumour cells. Its novel DUB technology platform integrates unique biology, screening, and chemistry capabilities to rapidly and effectively select and develop compounds targeting DUBs.

V
Vincere Biosciences

Vincere Biosciences develops small molecule therapeutics to improve mitochondrial quality. The company also develops disease-modifying therapies for Parkinson's disease. It is based in Cambridge, Massachusetts.

M
Mitokinin

Mitokinin is a biotechnology company focused on developing PINK1 targeted therapies for mitochondria-associated disorders, with a particular focus on Parkinson's Disease and certain forms of mitochondrial complex I disorders.On March 2nd, 2021, Mitokini was acquired by AbbVie. Terms of the transaction were not disclosed.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.